2015 American Transplant Congress
Does the C1q Assay Predict the Result of Lymphocyte Flow Cross-Match (FCxM) in Potential Renal Transplant Recipients With HLA-DSA and AHG-CDC CxM negative?
Background. The presence of pre-transplant HLA donor specific antibodies (DSA) is a recognized risk factor for acute rejection. However, due to the test's (LUMINEX) high…2015 American Transplant Congress
DSA Detected by ELISA-PRA Is Associated With High Risk for Development of AMR in Stable Kidney Transplant Recipients
Background: Donor specific anti-HLA antibodies (DSA) are a major cause of antibody mediated rejection (AMR) and allograft loss, determining how to monitor patients for DSA…2015 American Transplant Congress
Thymoglobulin Dosing Efficacy: The Role of ALC on Infection and Rejection
University of Minnesota, Minneapolis, MN.
There are varied Thymoglobulin® (Thymo) induction regimens accepted among transplant programs. Our center uses five doses of Thymo at 1.25mg/kg, yielding a total goal of…2015 American Transplant Congress
Delayed Graft Function in Patients Receiving Alemtuzumab Induction Therapy
1The University of Toledo Medical Center, Toledo, OH; 2The Alliance for Paired Donation, Maumee, OH.
Alemtuzumab (Campath 1-H) is a humanized monoclonal antibody directed at the CD52 glycoprotein that is becoming more prevalent as a choice for induction. Delayed graft…2015 American Transplant Congress
Analytic Morphomics May Identify Risk Factors for New Onset Diabetes After Kidney Transplantation
Intro:We have previously shown that analytic morphomics can predict risk of new-onset diabetes after liver transplantation (NODAT). We hypothesize that these methods may be able…2015 American Transplant Congress
Long-Term Outcome of Liver Transplant Recipients (OLT) With Hepatitis C Recurrence (HCVR) Who Achieved Postoperative Sustained Virologic Response (SVR) After Combination Antiviral Therapy (Rx) With and Without the Use of Telaprevir (TVR): A Single Center Experience
Liver Institute, Methodist Dallas Medical Center, Dallas, TX.
Aim: Liver allografts of viremic OLT have a higher risk of failure. Timely intervention is necessary. However, long-term outcome reports, especially using newer agents, is…2015 American Transplant Congress
Plasmapharesis, Intravenous Immunoglobulin and Rituximab Successfully Treat Recurrent Progressive Familial Intrahepatic Cholestasis Type 2 (PFIC-2) After Liver Transplantation
Background:Allo-immune mediated BSEP dysfunction may occur after liver transplantation in PFIC2 patients leading to a PFIC2 like phenotype. The IgG antibodies are reactive toward a…2015 American Transplant Congress
Neurocognitive Profile of Children Born to Kidney Transplant Recipients Mothers
Aim. To compare neurocognitive abilities of children of kidney transplant (KT) recipients who were exposed to immunosuppression during pregnancy with unexposed children. Methods. In this…2015 American Transplant Congress
Anti-CD122 + Costimulation Blockade Prolongs Allograft Survival
1Emory Transplant Center, Emory University, Atlanta, GA; 2JN Bioscience, Mountanview, CA.
Introduction: Effective T cell activation and effector function requires (1) cognate antigen recognition (2) appropriate costimulation and (3) successful cytokine signaling. Recently approved strategies to…2015 American Transplant Congress
Feasibility of Regulatory T Cell Cryopreservation and Banking for Clinical Therapeutic Applications
Feasibility of clinical application of regulatory T cells (Tregs) in clinical transplantation would be improved if Tregs or pre-enriched cells for Treg isolation could be…
- « Previous Page
- 1
- …
- 35
- 36
- 37
- 38
- 39
- …
- 170
- Next Page »